{"blog": [], "keywords": [{"value": "Johnson & Johnson", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Caplan, Arthur L", "name": "persons", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "New York University Langone Medical Center", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Merck & Company Inc", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Chimerix Inc", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Ethics and Official Misconduct", "name": "subject", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/07/business/company-creates-bioethics-panel-on-trial-drugs.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/05/07/business/Ethics/Ethics-thumbWide.jpg", "legacy": {"wide": "images/2015/05/07/business/Ethics/Ethics-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg", "xlargeheight": "936", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 936}, {"url": "images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1668", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved.", "pub_date": "2015-05-07T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Company Creates Panel for Access to Trial Drugs", "main": "Company Creates Bioethics Panel on Trial Drugs"}, "print_page": "1", "snippet": "Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved.", "_id": "554ae38d38f0d85a64346934", "slideshow_credits": null, "abstract": "Giant drug maker Johnson & Johnson is tapping renowned bioethicist Arthur L Caplan to form panel to evaluate requests by critically ill patients for access to potentially lifesaving, experimental medicines prior to their approval; issue is fraught with emotion and raises basic ethical questions about fairness and equal access to care; move by Johnson & Johnson could prompt other drug makers to follow suit."}